Tocagen Inc. (TOCA) financial statements (2021 and earlier)

Company profile

Business Address 1124 W CARSON STREET
TORRANCE, CA 90502
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:59229689
Cash and cash equivalents5994136
Short-term investments 135553
Other undisclosed cash, cash equivalents, and short-term investments (0)0 
Prepaid expense1   
Other undisclosed current assets1122
Total current assets:60239891
Noncurrent Assets
Operating lease, right-of-use asset 4
Property, plant and equipment0241
Other noncurrent assets1 10
Total noncurrent assets:1551
TOTAL ASSETS:612810392
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities281610
Accounts payable1332
Accrued liabilities15138
Debt 5 7
Deferred revenue and credits0
Other undisclosed current liabilities  00
Total current liabilities:2131717
Noncurrent Liabilities
Long-term debt and lease obligation 4264
Long-term debt, excluding current maturities  264
Operating lease, liability 4
Liabilities, other than long-term debt 020
Deferred revenue and credits0
Deferred rent credit  2
Other liabilities 0  
Total noncurrent liabilities: 4284
Total liabilities:2174521
Stockholders' equity
Stockholders' equity attributable to parent59115871
Common stock0000
Additional paid in capital110290274238
Accumulated other comprehensive income (loss) 0(0)(0)
Accumulated deficit(51)(279)(216)(167)
Total stockholders' equity:59115871
TOTAL LIABILITIES AND EQUITY:612810392

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
Revenue, net0
Gross profit: 0180
Operating expenses(46)(62)(64)(38)
Operating loss:(46)(62)(46)(38)
Nonoperating expense(0)  (1)
Other nonoperating expense(0)   
Interest and debt expense (4)(3)(2)
Loss from continuing operations before equity method investments, income taxes:(46)(65)(49)(41)
Other undisclosed income from continuing operations before income taxes 22 
Loss from continuing operations before income taxes:(46)(64)(47)(41)
Income tax expense (0)(2) 
Net loss:(46)(64)(49)(41)
Other undisclosed net income attributable to parent   2
Net loss available to common stockholders, diluted:(46)(64)(49)(39)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
Net loss:(46)(64)(49)(41)
Other comprehensive income (loss) 00(0)
Comprehensive loss:(46)(63)(49)(41)
Other undisclosed comprehensive income, net of tax, attributable to parent   2
Comprehensive loss, net of tax, attributable to parent:(46)(63)(49)(39)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: